Sort
21,453 grants matching “tuberculosis”
International Epidemiologic Databases to Evaluate AIDS-Southern Africa (IeDEA-SA)
$2,789,548Matthias Egger · Universitat Bern · U01 · FY2013 · AI
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)
$2,786,855Charles W. Flexner · Johns Hopkins University · UM1 · FY2020 · AI
Tuberculosis Imaging Program
$2,783,766Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIC · FY2023 · AI
Emory- Duke- Orlando- CDC (EmDOC) Clinical Trials Unit
$2,783,692Jeffrey Lennox · Emory University · UM1 · FY2018 · AI
Decoding the roles of critical genes of unknown function in M. tuberculosis
$2,782,563Eric Joseph Rubin · Harvard School Of Public Health · U19 · FY2015 · AI
Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)
$2,781,833Raphael Dolin · Beth Israel Deaconess Medical Center · UM1 · FY2015 · AI
Genes And Gene Products As Immunoadjuvants
$2,779,404Steven M Holland · Niaid Extramural Activities · Z01 · FY2007 · AI
COLLABORATIVE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA
$2,775,400Salim S Abdool Karim · University Of Kwazulu-Natal · U19 · FY2007 · AI
Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State University
$2,763,138Karen Marie Dobos · Colorado State University · UC7 · FY2025 · AI
University of Pennsylvania HIV Clinical Trials Unit
$2,761,412Ian Frank · University Of Pennsylvania · UM1 · FY2025 · AI
Epidemiology and transmission dynamics of MDR/XDR tuberculosis
$2,760,695Megan B Murray · Brigham And Women'S Hospital · U19 · FY2008 · AI
Determinants of TB control, relapse and reinfection
$2,755,450Sabine Ehrt · Weill Medical Coll Of Cornell Univ · U19 · FY2021 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression
$2,751,534David Alland · Rbhs-New Jersey Medical School · U19 · FY2021 · AI
Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State University
$2,751,527Karen Marie Dobos · Colorado State University · UC7 · FY2023 · AI
PItt-Ohio State-Georgetown Clinical Trials Unit
$2,751,253John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2020 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression
$2,749,420David Alland · Rutgers Biomedical And Health Sciences · U19 · FY2024 · AI
DEVELOPMENT OF TUBERCULOSIS VACCINE FORMULATIONS
$2,748,153Chris Fox · Access To Advanced Health Institute · N01 · FY2017 · AI
Metabolic factors that control the spectrum of human tuberculosis
$2,738,518David Branch Moody · Brigham And Women'S Hospital · U19 · FY2015 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit
$2,737,442Judith S. Currier · University Of California Los Angeles · UM1 · FY2014 · AI
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)
$2,736,516Ann R Falsey · University Of Rochester · UM1 · FY2022 · AI
TUBERCULOSIS CONTROL PROGRAM AND AIDS
$2,732,636Stephen, Phd Hughes · Nysdoh/Health Research, Inc. · U52 · FY2009 · PS
TB Clinical Diagnostics Research Consortium
$2,732,315Jerrold J. Ellner · Johns Hopkins University · N01 · FY2015 · AI
TUBERCULOSIS CONTROL PROGRAM AND AIDS
$2,731,107Stephen, Phd Hughes · Nysdoh/Health Research, Inc. · U52 · FY2008 · PS
TUBERCULOSIS ELIMINATION & LABORATORY
$2,723,696Michelle Conner · Georgia State Departmentof Public Health · U52 · FY2012 · PS
Bacterial and Host Heterogeneity in TB latency, persistence and progression
$2,722,689David Alland · Rutgers Biomedical And Health Sciences · U19 · FY2025 · AI